Safety alert against LeadCare Testing Systems by Magellan Diagnostics due to inaccurate test results

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: The U.S. Food and Drug Administration and Centers for Disease Control and Prevention are warning Americans that certain lead tests manufactured by Magellan Diagnostics may provide inaccurate results for some children and adults in the United States. Falsely lower test results may lead to improper patient management and treatment for lead exposure or poisoning.

The FDA is unable to identify the root cause for the inaccurate results, based on data provided by Magellan. We are conducting studies with the CDC to identify the cause and better characterize the extent of the problem. At this time, the FDA has no evidence that Magellan’s LeadCare Testing Systems have the same problem when processing capillary blood samples. The FDA is aggressively investigating the root cause of this issue with the manufacturers, health care facilities and the CDC, and will update this safety communication as critical information becomes available.  For more information please refer to the Safety Communication.

BACKGROUND: Magellan Diagnostics Inc. manufactures the following lead testing systems affected by this warning: LeadCare, LeadCare II, LeadCare Plus, and LeadCare Ultra.

The LeadCare Testing Systems detect the amount of lead in a blood sample obtained from finger or heel prick (capillary) or from a vein (venous). This warning applies to all four Magellan Diagnostics LeadCare Testing Systems when processing venous blood samples, in the United States.

Note: Magellan's LeadCare II is a point-of-care (CLIA-waived) blood lead testing system on which users mostly test capillary blood samples. However, some laboratories also process venous blood samples with the LeadCare II system, which is why this safety communication includes all Magellan LeadCare Testing Systems.

The LeadCare Testing Systems are used in clinical laboratories,...

Recommended for you

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of HeartMate II LVAS Pocket System Controller by Abbott-Thoratec- Controller malfunction after exchange

Read more
  • MedWatch Drug Updates
  • no comment

Gadolinium-based contrast agent for MRI- No adverse effects reported with gadolinium retention in the brain

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of V60 Non-invasive ventilator by Respironics- Unexpected stop in ventilation therapy

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Tri-Ton by Dynamic Technical Formulations LLC- Presence of unapproved drug andarine and ostarine

Read more
  • MedWatch Drug Updates
  • no comment

Drug safety alert: Canagliflozin (Invokana, Invokamet) may increase the risk of leg and foot amputations

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Radicava (edaravone) for amyotrophic lateral sclerosis

Read more
  • MedWatch Drug Updates
  • 1 comment

Safety alert against LeadCare Testing Systems by Magellan Diagnostics due to inaccurate test results

Read more
  • MedWatch Drug Updates
  • 1 comment

Use of Medtronic’s NavLock Tracker with non-Medtronic instruments can cause spinal injury or death

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Coronary Catheters by Abbott due to difficulty in removing the protective balloon sheath

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Rydapt (midostaurin) for acute myeloid leukemia

Read more
  • FDA Drug Updates
  • 1 comment

FDA expands approved use of Stivarga (regorafinib) for liver cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Brineura (cerliponase alfa) for Batten disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of 25% Dextrose Injection, USP, (Infant) by Hospira- Presence of particulate matter

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of GEC Laxoplex dietary supplement by Genetic Edge Compounds- Contaminated with anabolic steroids

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Ingrezza (valbenazine) for tardive dyskinesia

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of ventricular assist device controllers and DC adapter by Medtronic Mechanical Circulatory Support

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of the Wingman35 Crossing Catheters by ReFlow Medical- Tip splitting resulted in adverse events

Read more
  • FDA Drug Updates
  • no comment

FDA approved Ocrevus (ocrelizumab) for multiple sclerosis

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Zejula (niraparib) for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Dupixent (dupilumab) for atopic dermatitis

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Bavencio (avelumab) for Merkel cell carcinoma

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Xadago (safinamide) for Parkinson’s disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Drug safety alert: New warning on use of anesthetic/sedation drugs in young children, pregnant women

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA warning- Illegal selling of products that fraudulently claim to prevent, diagnose, treat or cure cancer

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Phenobarbital tablets, USP, 15 mg by C.O. Truxton- Mislabeling with incorrect strength

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Odactra for house dust mite allergies

Read more
  • FDA Drug Updates
  • 1 comment

Approval of Xermelo (telotristat ethyl) for carcinoid syndrome diarrhea

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA restricts use of codeine and tramadol in children and breastfeeding women-Risk of serious adverse reactions

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Siliq (brodalumab) for psoriasis

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Parsabiv (etelcalcetide) for hyperparathyroidism in dialysis patients

Read more